Ultra-long-acting treatment could reshape respiratory care as EU regulators back GSK's high-stakes depemokimab ahead of 2026 ...

If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist ...

Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

CHEST guidelines on biologic management in severe adult asthma offers recommendations on choosing and switching among biologic therapies.

Asthma is a major burden worldwide, for governments, health-care providers, patients and their carers, 1 and there is considerable variation in asthma prevalence, morbidity and mortality. 2 Asthma ...

IN 2010 AN American girl called Emily Whitehead developed a form of leukaemia that is usually terminal. She was five years old. Two years later, she became the first paediatric patient to be offered a ...

Around 88% of primary care providers managing patients with uncontrolled asthma reported being unfamiliar or only somewhat ...

The injection is recommended as an additional maintenance treatment for patients over 12 when usual medications have not ...

FeNO testing is increasingly recognized as a key first step in asthma assessment under the updated UK guidelines.

The authors write that once severe asthma is diagnosed, clinicians should determine asthma endotype (Type2-high or Type2-low) to help choose the best therapy for the patient. Asthma endotype, clinical ...